Dyne Therapeutics

Compare

401 Followers

DYN Stock Chart & Stats

$24.29

-$0.74(-3.10%)

At close: Jan 08 4:00 PM EST

$24.29

-$0.74(-3.10%)

Day’s Range― - ―

52-Week Range$6.36 - $35.68

Previous CloseN/A

Volume117.44K

Average Volume (3M)2.41M

Market Cap

$2.44B

Enterprise Value$521.22M

Total Cash (Recent Filing)$683.92M

Total Debt (Recent Filing)$22.26M

Price to Earnings (P/E)―

Beta2.09

Next Earnings

Oct 30, 2025

EPS Estimate

-0.84

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.97

Shares Outstanding142,263,730

10 Day Avg. Volume2,094,042

30 Day Avg. Volume2,413,069

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.21

Enterprise Value/Revenue331.57

Enterprise Value/Gross Profit1.82K

Enterprise Value/Ebitda-1.19

Forecast

1Y Price Target

$36.67

Price Target Upside50.97% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Acquisition And Market ValidationThe acquisition of Avidity Biosciences is seen as a positive signal for Dyne Therapeutics, validating the RNA therapeutics landscape and big pharma's interest in this space.

FDA Support And DesignationThe FDA granted Breakthrough Therapy Designation to DYNE-251 for the treatment of patients with Duchenne muscular dystrophy, highlighting unmet need and FDA support.

Therapies Approval PotentialThe potential for accelerated approval positions Dyne Therapeutics to be first-to-market with its therapies.

Bears Say

Dyne Therapeutics News

Dyne Therapeutics rises 41.7%

Dyne Therapeutics (DYN) is up 41.7%, or $7.14 to $24.26. Published first on TheFly – the ultimate source...

2d ago

DYN

Dyne Therapeutics rises 42.4%

Dyne Therapeutics (DYN) is up 42.4%, or $7.26 to $24.38. Published first on TheFly – the ultimate source...

2d ago

DYN

Video: Merger Monday with deals announced in biotechnology and banking

The Fly has brought its to-the-moment stock market reporting to YouTube! Subscribe if you want to know how...

2d ago

AWK

DYN

Avidity acquisition has positive read for Dyne Therapeutics, says Morgan Stanley

After Novartis (NVS) announced an agreement to acquire Avidity Biosciences (RNA), including its proprietary Antibody Oligonucleotide Conjugate platform...

2d ago

DYN

NVS

Dyne Therapeutics up 37% after Avidity gets bought

Shares of Dyne Therapeutics (DYN) are up $6.40, or 37%, to $23.52 in pre-market trading after Novartis (NVS)...

2d ago

DYN

NVS

Dyne Therapeutics downgraded to Perform at Oppenheimer following additional data

As previously reported, Oppenheimer downgraded Dyne Therapeutics (DYN) to Perform from Outperform but kept a price target of...

19d ago

DYN

Dyne Therapeutics downgraded to Perform from Outperform at Oppenheimer

Oppenheimer downgraded Dyne Therapeutics (DYN) to Perform from Outperform. Published first on TheFly – the ultimate source for...

19d ago

DYN

Dyne announces additional one-year data from ACHIEVE study

Dyne Therapeutics (DYN) last night announced additional one-year data from its ongoing Phase 1/2 ACHIEVE clinical trial of...

22d ago

DYN

Dyne Therapeutics Advances DYNE-101 Study for Myotonic Dystrophy Type 1

Dyne Therapeutics, Inc. (($DYN)) announced an update on their ongoing clinical study. Dyne Therapeutics, Inc. is conducting a...

2d ago

DYN

Dyne Therapeutics: Positioned for Growth in the RNA Therapeutics Market Amid Industry Validation

Analyst Francois Brisebois of LifeSci Capital maintained a Buy rating on Dyne Therapeutics, boosting the price target to...

2d ago

DYN

Dyne Therapeutics Positioned for Growth with FORCE Platform and Key Upcoming Catalysts

Dyne Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Ulz from...

2d ago

DYN

Dyne Therapeutics: Promising Advancements in Neuromuscular Treatments Drive Buy Rating

Dyne Therapeutics (DYN) has received a new Buy rating, initiated by LifeSci Capital analyst, Francois Brisebois. Francois Brisebois...

15d ago

DYN

Dyne Therapeutics Elects Brian Posner to Board

An announcement from Dyne Therapeutics ( ($DYN) ) is now available. On October 1, 2025, Dyne Therapeutics, Inc....

27d ago

DYN

Dyne Therapeutics receives orphan drug designation in Japan for DYNE-251 in DMD

Dyne Therapeutics (DYN) announced that the Ministry of Health, Labour and Welfare in Japan has granted Orphan Drug...

1M ago

DYN

DYN FAQ

What was Dyne Therapeutics’s price range in the past 12 months?

Dyne Therapeutics lowest stock price was $6.36 and its highest was $35.68 in the past 12 months.

What is Dyne Therapeutics’s market cap?

Dyne Therapeutics’s market cap is $2.44B.

When is Dyne Therapeutics’s upcoming earnings report date?

Dyne Therapeutics’s upcoming earnings report date is Oct 30, 2025 which is tomorrow.

How were Dyne Therapeutics’s earnings last quarter?

Dyne Therapeutics released its earnings results on Jul 28, 2025. The company reported -$0.97 earnings per share for the quarter, missing the consensus estimate of -$0.942 by -$0.028.

Is Dyne Therapeutics overvalued?

According to Wall Street analysts Dyne Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Dyne Therapeutics pay dividends?

Dyne Therapeutics does not currently pay dividends.

What is Dyne Therapeutics’s EPS estimate?

Dyne Therapeutics’s EPS estimate is -0.84.

How many shares outstanding does Dyne Therapeutics have?

Dyne Therapeutics has 142,263,730 shares outstanding.

What happened to Dyne Therapeutics’s price movement after its last earnings report?

Dyne Therapeutics reported an EPS of -$0.97 in its last earnings report, missing expectations of -$0.942. Following the earnings report the stock price went down -1.182%.

Which hedge fund is a major shareholder of Dyne Therapeutics?

Currently, no hedge funds are holding shares in DYN

Dyne Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-61.32%

Trailing 12-Months

Asset Growth

-11.73%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Dyne Therapeutics

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Dyne Therapeutics (DYN) Earnings & Revenues

Historic Earnings Reports

DYN Stock 12 Month Forecast

Average Price Target

$36.67

▲(50.97% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","28":"$28","49":"$49","17.5":"$17.5","38.5":"$38.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$48.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$36.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,17.5,28,38.5,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.5,15.23076923076923,17.96153846153846,20.692307692307693,23.423076923076923,26.153846153846153,28.884615384615387,31.615384615384617,34.34615384615385,37.07692307692308,39.80769230769231,42.53846153846154,45.269230769230774,{"y":48,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.5,14.35923076923077,16.21846153846154,18.07769230769231,19.93692307692308,21.79615384615385,23.655384615384616,25.514615384615386,27.373846153846156,29.233076923076926,31.092307692307696,32.95153846153846,34.81076923076923,{"y":36.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.5,12.538461538461538,12.576923076923077,12.615384615384615,12.653846153846153,12.692307692307692,12.73076923076923,12.76923076923077,12.807692307692308,12.846153846153847,12.884615384615385,12.923076923076923,12.961538461538462,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":34.76,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.74,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.28,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.56,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.61,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.7,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.68,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.05,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >